RNA PLATFORM
During the pandemic, RNA technology has come to the forefront for its safety, efficacy and rapid development potential.
We have established and are scaling up the three major components required for the development and production of RNA therapeutics:
​
-
plasmid DNA construct design and purification
-
mRNA synthesis and purification
-
lipid nanoparticle encapsulation​​
If you are interested in accessing RNA vaccines and therapeutics for your research, please get in touch with Rebecca McKenzie at rmckenzie@malaghan.org.nz
INSTRUMENTATION
The Hugh Green Technology Centre has access to two Lipid Nanoparticle Assemblers, the Ignite and the Blaze from Precision Nanosystems Inc. These are essential instruments for the generation of RNA therapeutics as they allow for generation of liquid nanoparticles of a consistent size and low polydispersity. The same process used in pre-clinical scale production of mRNA/LNPs can be scaled up to larger manufacturing production, saving time bringing a product to the market.
The Hugh Green Technology Centre and the National RNA Platform are working together to implement the technologies housed in the genomics core to support the successful development of RNA vaccines, therapeutics and their translation to the clinic.
For more information visit the Ribonucleic Acid (RNA) Development Platform website: https://www.wgtn.ac.nz/ferrier/research/rnaplatform
.png)
Ignite Nanoparticle Assemblr
AKTA Avant 25 FPLC System